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The most common cause of hyperthyroidism is Graves' disease. TRH 
and TSH are hormonal factors that modulate and control thyroid function in 
Graves' disease. In the immunological aspect, Graves' disease is played by 
the role of T-reg, IL-4, and anti-TPO. Graves' disease treatment goal is to 
inhibit thyroid hormone secretion by administering thionamide. The 
evaluation of this treatment is its hormonal and immunological aspects. To 
describe the effect of thionamide on serum TRH, TSH, IL-4, T-reg, and anti-
TPO levels in Graves' disease. This study is a clinical trial study in 25 study 
participants. All study participants were given thionamide, namely PTU 
300mg for three months and blood samples were taken for laboratory tests. 
Serum TRH, TSH, IL-4, T-reg FOXP3, and anti-TPO levels were examined by 
ELISA. The mean levels at the beginning and after three months of therapy 
are: serum TRH 92.589pg/mL and 115.944pg/mL; serum TSH 0.041mU/L 
and 0.223mU/L; serum IL-4 19.759pg/mL and 23.040pg/mL; T-reg FOXP3 
gene polymorphism 0.621ng/mL and 0.518 ng/mL; serum anti-TPO 
2697.539pg/mL and 2604.710pg/mL. Increased levels of serum TRH and 
TSH levels were statistically significant. The change in serum IL-4, T-reg 
FOXP3 gene polymorphism, and anti-TPO levels were not statistically 
significant. The administration of thionamide in Graves' disease for three 
months will significantly decrease Wayne index and serum FT4 levels, 
increase serum TRH and TSH levels. 
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INTRODUCTION  
The most common cause of hyper-
thyroidism in the world is Graves' disease. Graves' 
disease occurs in 2 - 2.5% of women and 0.2 - 0.6% 
of men. The factors that play a role in Graves' 
disease are environment, genetic disorders, and 
autoimmune processes. Thyroid-stimulating 
hormone (TSH) is one of the links in a complex 
signaling network that modulates and controls 
thyroid growth and function in Graves' disease. 
TSH not only works at glands and thyroid function. 
TSH circulating in the tissues is controlled by 
thyrotropin-releasing hormone (TRH) levels and 
the feedback effect of thyroid hormone levels on 
the tissues. In the immunological aspect of Graves' 
disease, at higher level, is controlled by T-regulator 
(T-reg) cells. In the next stage, the T-reg will 
differentiate T-helper (Th) cells which is will 
produce various inflammatory cytokines, including 
interleukin-4 (IL-4). In addition to T-reg cells, B 
cells have role in humoral to produce several 
antibodies, one of them is anti-TPO (Lillevang-
Johansen et al., 2017; Wang et al., 2012; Elvira et 
al., 2017).  
 
The stages of biosynthetic processes and 
secretions of thyroid hormones are stimulated by 
TSH. Thyroid hormone levels are controlled by 
TSH, which is produced by the anterior pituitary 
gland. TSH levels are regulated by TRH produced 
by the hypothalamus gland. Then, thyroid hormones 
will provide negative feedbacks to pituitary gland 
and hypothalamus (Davies et al., 2011) 
Graves' disease is not only explained by the 
theories of comparison Th1 and Th2. Lately 
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attention has been paid to T-reg cells. Initially T-
reg cells are described as CD4 + suppressor cells. 
Later, regulatory T cells (T-reg) are known as 
subtypes of CD4 which has specificities in the 
presence of CD25 expression, where the 
expression of the Forkhead box P3 (FOXP3) 
molecule is a special marker from T-reg. CD4 + 
CD25 + Foxp3 + Natural T-reg is considered as the 
main component of T-reg cells and emerges from 
the thymus as fully differentiated cells. And the 
abnormality of the T-reg number and its function 
has an effect on several autoimmune diseases 
(Elvira et al., 2017; Elvira et al., 2016) 
Interleukin-4 is the main cytokine that 
associated with autoimmune thyroid disease. IL-4 
plays a main role in the process of differentiating 
naïve T cells into Th cells and increasing the 
expression of MCH class II in B cells, dendritic cells 
and macrophage cells. IL-4 stimulates the isotype 
of Immunoglobulin G3 (IgG3-SCS) secreting cell 
which is associated with the severity of Graves' 
disease. The increase in cytokine values in Graves' 
patients illustrate the activity and interplay of Th1 
and Th2 which are compatible with long-term 
inflammation and the damage process of the 
thyroid gland (Decroli et al., 2014). 
Anti-thyroid peroxidase antibodies (anti-
TPO) are antibodies that bind to transmembrane 
proteins in tyrosite which are involved in the 
synthesis of thyroid hormones. Anti-TPO is also 
known as an microsomal anti-thyroid antibodies 
which is an important examination in autoimmune 
thyroid disease because it is found to be positive in 
more than 80% of patients with Graves' disease. 
There is some laboratory examination to describe 
hyperthyroid in Graves’ disease, such as: Total T3, 
Total T4, FT3 and FT4. FT4 is an important 
laboratory examination because FT4 have longer 
half-life and not influenced by serum albumin 
levels. In addition, Wayne index that represented 
the symptoms and clinical manifestation including 
vital sign of Graves’ disease is also important in 
assessing the patient’s performance (Davies et al., 
2011). 
In general, the goal of treating 
hyperthyroidism in Graves' disease is to inhibit 
thyroid hormone secretion. One of the effective 
treatment for hyperthyroidism is antithyroid 
agents, which is thionamide. Antithyroid treatment 
consists of initial and maintenance therapy. Initial 
therapy is given until serum FT4 levels are normal. 
Initial therapy ranges from 4 to 12 weeks. After 
achieving normal serum FT4 levels, maintenance 
therapy begins by reducing the dose of thionamide 
by 50% (Davies et al., 2011; Elvira et al., 2016; 
Decroli et al., 2014). 
The Wayne index, serum FT4 and TSH levels 
are evaluated in the treatment of Graves' disease. 
Meanwhile, TRH levels have not been evaluated. 
The effect of therapy on Graves' disease should 
also influence the factors that play a role in 
immunological aspects, such as T-reg, IL-4, and 
anti-TPO. In this study, we want to see the effect of 
thionamide on levels of TRH, TSH, IL-4, T-reg, and 
anti-TPO in Graves' disease (Davies et al., 2011; 
Elvira et al., 2016; Decroli et al., 2014). 
 
MATERIAL AND METHODS 
This study is a clinical trial study with pre 
and post treatment to the study sample. This study 
involved 25 patients with Graves' disease who had 
not received prior treatment and who controlled to 
the metabolic endocrine clinic at the RSUP Dr. M. 
Djamil Padang who has signed the informed 
consent. Pregnant patients, allergic to thionamide, 
and Graves’ relapse were excluded. All study 
participants were given initial therapy for three 
months of thionamide antithyroid treatment, PTU 
300mg. All blood samples have taken from this 
study participants for laboratory tests at the 
beginning and at the end of initial therapy. We 
examined variables like serum TRH, TSH, IL-4, T-
reg FOXP3 gene polymorphism, and anti-TPO 
levels. This research has received an ethical 
approval from the Ethics Committee of Medical 
Faculty of Andalas University. 
 
Methods  
Serum TRH, TSH, IL-4, T-reg FOXP3, and 
anti-TPO levels were examined with enzyme-
linked immunosorbent assay techniques (ELISA) 
method. The variables examinations were using 
Elabscience Biotechnology experimental kits. 
There are several steps in this examination 
process. Add 100L sample each well. Incubate for 
90 minutes at 37ᵒC. Remove the liquid. Add 100L 
Biotinylated Detection Ab. Incubate for one hour at 
37ᵒC. Aspirate and wash 3 times. Add 100L HRP 
Conjugate. Incubate for 30min at 37ᵒC. Aspirate 
and wash 5 times. Add 90L Substrate Reagent. 
Incubate for 15min at 37ᵒC. Add 50L Stop 
Solution. Read at 450nm immediately. And then, 
calculate the results. 
Statistical analysis was carried out by 
comparing serum TRH, TSH, IL-4, T-reg FOXP3 
gene polymorphism, and anti-TPO levels at the 
beginning and at the end of three months therapy 
of  thionamide.  Paired  t-test  was  used  to   analyze 
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the differences of before and after the three 
months therapy. A value of p <0.05 was considered 
as significant. 
 
RESULT AND DISCUSSION 
The baseline characteristics of this study 
(Table I). From the study, the range of patients’ age 
are from 17 to 33 years, with the average of age is 
27.48 (5.6) years. The number of female patients in 
this study is more than male patients, with 
percentage of women are 96% and men are 4%. In 
this study, only one from the men patients was 
attended at the study. The average of age from this 
study’s sample is smaller than some other studies. 
The average of age was obtained in this study is 
appropriate with The Indonesian Society of 
Endocrinology Task Force on Thyroid Diseases 
(2012) which states that Graves’ disease appears 
more frequently at the third and fourth of decades 
(The Indonesian Society of Endocrinology, 2012; 
Voskuhl, 2011). 
The higher percentage of women than men 
was also found by Voskuhl (2011). Voskuhl (2011) 
states that women are more prone to suffer               
from autoimmune disorders. This is in accordance 
with Ngo et al (2014) which states that 
autoimmune disorders are more common in 
women. There are several studies that gave the 
prevalence of autoimmune disorders in several 
countries. Carle et al (2011), Gaujoux et al (2006), 
Guo et al (2013), and Phitayakorn et al (2013) 
reported that Graves’ disease was more prevalent 
among women in the United States, France, 
Denmark, and China. The Indonesian Society of 
Endocrinology Task Force on Thyroid Diseases 
(2012) states that the ratio of women to men with 
Graves’ disease is 8:1 (The Indonesian Society of 
Endocrinology, 2012; Voskuhl, 2011; Ngo et al., 
2014). 
Changes in vital signs, Wayne index and 
serum FT4 levels at initial and after three months 
of   thionamide    therapy   (Table  II  and  Table III).  
Table I. Baseline Characteristics 
 
Characteristics (n=25) Mean (SD) Median n (%) 
Average Age (yo) 27.48 (5.6)   
Sex 
Male 
Female 
   
1 (4%) 
24 (96%) 
Heart Rate (beats/minute) 110.40 (6.63)   
Systolic Blood Pressure (mmHg) 139.48 (6.63)   
Diastolic Blood Pressure (mmHg) 63.48 (8.64)   
Pulse Pressure (mmHg) 76.00 (11.77)   
Temperature (0C) 37.62 (0.51)   
Wayne Index 23.44 (1.4)   
FT4 (pmol/L) 55.55 (17.98)   
TRH (mU/L)  92.589  
TSH (pg/mC) 
T-reg FOXP3 gene polymorphism (ng/mL) 
IL-4 (pg/mL) 
Anti-TPO (pg/mL) 
 
0.621 (0.23) 
19.759 (7.03) 
2697.539 (479.72) 
0.041 
 
 
 
Table II. Changes in vital signs at initial and after three months of thionamide therapy 
 
Variable 
Mean 
p 
Initial (n=25) After three months (n=25) 
Heart Rate (beats/minute) 110.40 (6.63) 82.12 (5.07) 0.001 
Systolic Blood Pressure (mmHg) 139.48 (6.63) 121.12 (5.39) 0.001 
Diastolic Blood Pressure (mmHg) 63.48 (8.64) 77.32 (6.38) 0.001 
Pulse Pressure (mmHg) 76.00 (11.77) 43.80 (9.55) 0.001 
Temperature (0C) 37.62 (0.51) 36.87 (0.28) 0.069 
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Heart rate, systolic blood pressure, and pulse 
pressure are decreased after initial thionamide 
therapy. But, there is no significant changes in 
temperature. The decreased of Wayne index and 
serum FT4 levels are statistically significant. These 
showed that initial therapy of thionamide can 
improve the patient’s performance. Davies et al 
(2011) also found that initial therapy of 
thionamide will decreased nervousness, 
palpitation and heart rate, increased strength, and 
weight gain. The decreased of these parameters 
are important to evaluate the outcome of therapy 
(Davies et al., 2011). 
Changes in serum TRH and TSH levels at 
initial and after three months of thionamide 
therapy (Table IV). Median of serum TSH level 
before administration of thionamide in this study 
was 0.041 mU/l. After giving thionamide for three 
months, the median of serum TSH level was 0.223 
mU/L. There was an increase in serum TSH level 
after administration of thionamide for three 
months, statistically significant. This result is 
supported by Schimdt and Braunbeck (2011) who 
stated that zebrafish who get thionamide will 
experience thyroid gland hyperplasia and 
increased blood vessel flow in the thyroid gland 
tissue. Immunohistological staining at cells which 
are producing TSH in the pituitary shows a 
significant increase. This indicates that an increase 
occurs in serum TSH levels of zebrafish after the 
administration of thionamide (Schmidt et al., 
2011). 
Median serum TRH level before 
administration of thionamide in this study was 
92.589 pg/mL. After giving thionamide for three 
months, the median serum TRH level was 115.944 
pg/mL There was an increase in TRH levels after 
the administration of thionamide for three months, 
which is statistically significant. Propylthiouracil is 
effective in reducing thyroid hormone levels back 
to normal with the initial therapy for three 
months. This decrease in thyroid hormone levels 
will be followed not only by increased in TSH 
levels, but also by an increase in TRH levels 
through the hypothalamic-pituitary-thyroid axis. 
(Alkemade, 2015; Guissouma et al., 2002). 
Changes in serum T-reg FOXP3 
polymorphism serum, IL-4 and anti-TPO levels at 
initial and after three months of thionamide 
therapy (Table V). The mean T-reg FOXP3 
polymorphism before administration of 
thionamide in this study was 0.621 ng/ml. After 
giving thionamide for three months, the average T-
reg FOXP3 polymorphism in this study was 
0.518ng/mL. The change in FOXP3 T-reg 
polymorphism statistically was not significant. 
Table III. Changes in Wayne index and FT4 serum levels at initial and after three months of thionamide 
therapy 
 
Variable 
Mean 
p 
Initial (n=25) After three months (n=25) 
Wayne index 23.44 (1.42) 11.80 (1.47) 0.001 
FT4 Serum (pmol/L) 55.55 (17.98) 9.44 (2.67) 0.001 
 
Table IV. Changes in TRH and TSH serum levels at initial and after three months of thionamide therapy 
 
Variable 
Median 
p 
Initial (n=25) After three months (n=25) 
TRH Serum (pg/mL) 92.589 115.944 0.001 
TSH Serum (mU/L) 0.041 0.223 0.001 
 
Tabel V. Changes in serum T-reg FOXP3 polymorphism, IL-4 and anti-TPO levels at initial and after three 
months of thionamide therapy 
 
Variable 
Mean 
p 
Initial (n=25) After three months (n=25) 
T-reg FOXP3 gene polymorphism (ng/mL) 0.621 (0.23) 0.518 (0.25) 0.124 
IL-4 (pg/mL) 19.759 (7.03) 23.040 (7.35) 0.150 
Anti-TPO (pg/mL) 2697.539 (479.72) 2604.710 (458.80) 0.361 
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The mean serum IL-4 level before 
administration of thionamide in this study was 
19.759pg/mL. After giving thionamide for three 
months, the mean serum IL-4 level in this study 
was 23,040 pg/mL. This change in IL-4 levels 
statistically was not significant. The mean serum 
anti-TPO level before administration of thionamide 
in this study was 2,697,539 pg/mL. After giving 
thionamide for three months, the mean serum 
anti-TPO level in this study was 2,604,710 pg/mL. 
This change in the level of anti-TPO statistically 
was not significant. 
Humar et al (2008) explained that 
thionamide is an antithyroid drug with 
immunomodulating effects. This was proven in his 
research that showed thionamide which inhibited 
the synthesis of proinflammatory cytokines TNF- 
and interferon-. Decroli et al (2014) found that 
administration of thionamide for one year would 
reduce IL-4 levels. Levels of IL-4 were found to 
drop dramatically in the first six months of 
thionamide therapy. However, the influences of 
thionamide on T-reg and anti-TPO has not been 
widely discussed (Decroli et al., 2014; Humar et al., 
2008). 
This study shows that the administration of 
initial therapy of thionamide for three months will 
improve Graves’ disease hormonally, which are 
normal levels of FT4, significantly increased TSH 
and TRH serum levels. In this study, there were no 
significant changes in the FOXP3 T-reg gene 
polymorphism, IL-4 levels, and anti-TPO serum. It 
explains that the importance to continue the 
administration of thionamide in Graves’ disease to 
see its immunological effects (Elvira et al., 2017; 
Decroli et al., 2014; Lauberg et al., 2014). 
 
CONCLUSION 
The administration of thionamide in Graves’ 
disease for three months will significantly 
decrease Wayne index and serum FT4 levels, 
increase serum TRH and TSH levels. 
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